Global chemotherapy development for gastric cancer

Harada, Kazuto; Kaya, Dılşa Mızrak; Shimodaira, Yusuke; Ajani, Jaffer A.

doi:10.1007/s10120-016-0655-8

Cited by 44 publications

(31 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multidisciplinary therapies employing surgical resection followed by adjuvant chemoradiation treatment, have been increasingly performed as the treatment modality in patients with resectable digestive tract cancers [17,18]. However, controversy was remained existed about whether the multidisciplinary therapies could result in a survival improve effects in patients with adenocarcinoma of the appendix.…”

Section: Discussionmentioning

confidence: 99%

Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China

Wang

Zhai

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: To investigate the clinical and pathological characteristics of appendiceal mucinous adenocarcinoma with peritoneal metastasis and analyze the prognostic factors. Methods: A retrospective analyses of clinicopathological features of 50 patients with appendiceal mucinous adenocarcinoma with peritoneal metastasis from January, 2013 to December, 2017 in Aerospace Central Hospital, Beijing, China. Survival data calculation and comparison were respectively performed with the Kaplan-Meier method and the log-rank test. The Cox proportional hazards regression method was used for multivariate survival analyses. Results: Cytoreduction for appendiceal mucinous adenocarcinoma was conducted on 50 patients (24 males and 26 females), with a median age of 52.5 years at the time of surgery (range 31-71 years). The median overall survival (OS) time was 24 months, with 2-,3-and 5-year survival rates of 53, 24 and 8%, respectively. At the last follow-up in December 2018, 13 patients were still alive. Multivariate analysis revealed that patients who had low Ki-67 expression (less than 50%) and CCR (completeness of cytoreduction) 0/1/2 score had significantly better OS rate than their respective counterparts. Conclusions: Ki-67 expression statue and CCR score could be employed as the prognosis prediction in patients with appendiceal mucinous adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China

Wang

Zhai

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…It should be noted that multidisciplinary therapies, especially surgical resection followed by adjuvant chemoradiation therapy, have been increasingly applied for the treatment of suitable patients with resectable digestive tract cancers16171819. However, whether multidisciplinary therapies could improve overall survival in patients with adenocarcinoma of the appendix remains uncertain.…”

Section: Discussionmentioning

confidence: 99%

The Management and Prognostic Prediction of Adenocarcinoma of Appendix

Xie

Zhou

Song

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Malignant tumours of the appendix are quite rare, especially appendiceal adenocarcinomas, which may be difficult to detect preoperatively or intraoperatively. We collected data for 1404 patients with adenocarcinoma of the appendix from the Surveillance, Epidemiology, and End Results Program (SEER) database to explore the potential associations between clinicopathological factors and overall survival. Furthermore, a novel nomogram for predicting prognosis was developed based on our analysis of the SEER data. The nomogram prediction model included seven prognostic factors derived based on different clinical estimates. When compared with the traditional tumour-node-metastasis (TNM) staging system, the nomogram prediction model showed superior discriminatory power (Harrell’s C-index, 0.741 vs. 0.686) and a greater degree of similarity to actual 5-year overall survival after calibration (Akaike Information Criterion index, 5270.781 vs. 5430.141). Finally, we provide recommendations for the management of patients with adenocarcinoma of the appendix. Notably, we found the depth of adenocarcinoma invasion may be used as an indicator to determine the optimal surgical approach. For mucinous adenocarcinomas of the appendix, because these tumours are characterized by unique biological behaviour, intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is recommended. However, whether systematic chemotherapy should be administered to patients with adenocarcinoma of the appendix requires further investigation.

show abstract

“…Median PFS was 4.8 months with chemotherapy and 7.9 months with chemotherapy plus IMAB362 (HR = 0.47, P = 0.0001), whereas median OS was 8.4 months versus 13.2 months, respectively (HR = 0.51, P = 0.0001). The benefit was more pronounced among patients with high expression of CLDN18.2; staining in ≥70% of tumor cells [51].…”

Section: New Therapiesmentioning

confidence: 94%

Medical management of gastric cancer: a 2017 update

et al. 2017

Self Cite

View full text Add to dashboard Cite

Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence‐based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer.

show abstract

Global chemotherapy development for gastric cancer

Cited by 44 publications

References 95 publications

Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China

Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China

The Management and Prognostic Prediction of Adenocarcinoma of Appendix

Medical management of gastric cancer: a 2017 update

Contact Info

Product

Resources

About